Business Wire

Public formulary and program coverage makes AJOVY® accessible to more migraine patients across Canada MONTRÉAL--(BUSINESS WIRE)--Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., welcomes the recently announced public formulary

More

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM” is pleased to announce that Doug Drysdale, Cybin’s Chief Exe

More

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and dev

More

QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical p

More

MISSISSAUGA, Ontario--(BUSINESS WIRE)--$MDX #SkinCancer--MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it is proposing a non-brokered Private Placement to accredited investors of up to $4 million by issuance

More

VANCOUVER, British Columbia--(BUSINESS WIRE)--$CALM #canadiansecuritiesexchange--REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) is pleased to announce its collaboration with PharmaTher

More

2021 Revenue of $9.4M compared to $4.3M in 2020, an increase of 121% 2021 Gross Profit of $5.2M (56% margin), before fair value adjustments, compared to $1.8M (43% margin) in 2020, an increase of 188% and 1300 basis points 2021 aEBITDA1 of $2.2M (24

More

- For the Treatment of the Symptoms of Seasonal Allergic Rhinitis and Chronic Spontaneous Urticaria (such as itchiness and hives) - - 2.5mg/mL Oral Solution and (rapidly dispersing)10mg Orodispersible (Quick Melt) Tablet Formats - MISSISSAUGA, Ontario--

More

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and oth

More

CHATHAM, Ontario--(BUSINESS WIRE)--#alternativeassets--First paragraph, second sentence of release dated February 15, 2022 should read: "... are up 633% from December of 2020." (instead of "...are up 633% from December of 2021."). The updated release rea

More